TrialBreast cancer research and treatment2019

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Véronique Diéras et al.PubMed ↗Publisher ↗

No numbers read from the abstract.